Free tool
FAERS Monitor: Mylotarg
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761060 or its brand name (Mylotarg, Gemtuzumab Ozogamicin). Reports on generic versions are filed under their own applications.
Reports
3,665
Serious
3,554
97% of reports
Hospitalization
1,753
Death reported
1,135
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- febrile neutropenia698
- pyrexia326
- sepsis302
- venoocclusive liver disease260
- thrombocytopenia240
- platelet count decreased236
- pneumonia197
- neutropenia194
- white blood cell count decreased185
- aspartate aminotransferase increased184
- off label use174
- alanine aminotransferase increased163
- drug ineffective163
- chills158
- acute myeloid leukaemia151
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 127 |
| 2005 | 156 |
| 2006 | 311 |
| 2007 | 192 |
| 2008 | 118 |
| 2009 | 135 |
| 2010 | 135 |
| 2011 | 200 |
| 2012 | 101 |
| 2013 | 64 |
| 2014 | 52 |
| 2015 | 83 |
| 2016 | 77 |
| 2017 | 122 |
| 2018 | 221 |
| 2019 | 177 |
| 2020 | 259 |
| 2021 | 315 |
| 2022 | 242 |
| 2023 | 220 |
| 2024 | 149 |
| 2025 | 129 |
| 2026 | 77 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,494 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| venoocclusive liver diseaseSignal | 260 | 318.9 | 282.7 | 77,775 |
| febrile neutropeniaSignal | 698 | 61.0 | 57.1 | 40,842 |
| acute myeloid leukaemiaSignal | 151 | 56.1 | 48.0 | 8,049 |
| aspartate aminotransferase increasedSignal | 184 | 19.9 | 17.3 | 3,289 |
| sepsisSignal | 302 | 15.6 | 14.0 | 4,116 |
| alanine aminotransferase increasedSignal | 163 | 15.3 | 13.1 | 2,161 |
| platelet count decreasedSignal | 236 | 12.7 | 11.3 | 2,547 |
| thrombocytopeniaSignal | 240 | 12.3 | 10.9 | 2,498 |
| white blood cell count decreasedSignal | 185 | 9.8 | 8.5 | 1,460 |
| neutropeniaSignal | 194 | 8.2 | 7.1 | 1,225 |
| chillsSignal | 158 | 7.7 | 6.6 | 925 |
| pyrexiaSignal | 326 | 5.4 | 4.9 | 1,186 |
| pneumoniaSignal | 197 | 3.5 | 3.0 | 353 |
| off label use | 174 | 1.1 | 1.0 | 3 |
| drug ineffective | 163 | 0.7 | 0.6 | 20 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.